ArticleCurrent microbiology2025
In vitro and In Vivo Antimicrobial Activity of Melia Azedarach-Mediated Copper Oxide Nanoparticles Against Multidrug-Resistant Klebsiella pneumoniae.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antibiotic resistance inFrontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increasing prevalence of multidrug-resistant pathogens such as Klebsiella pneumoniae, which causes pneumonia and acute respiratory distress syndrome (ARDS) with high mortality rates, poses a significant clinical challenge. Fourth-generation antibiotics, such as cefepime, are often considered the last line of defense against these pathogens. The emergence of cefepime-resistant K. pneumoniae (CRKP) compromises the efficacy of available antibiotics and highlights the importance of new alternative therapies. This study directed the phyto-synthesis of copper oxide (CuO) nanoparticles using Melia azedarach leaf extract and evaluated their antibacterial efficacy, both individually and synergistically with cefepime, against multidrug-resistant Klebsiella pneumoniae through in vitro and in vivo models. The phyto-synthesized copper oxide nanoparticles were characterized using UV-Vis spectroscopy, Fourier transform infrared spectroscopy (FTIR), field emission scanning electron microscopy (FESEM), and energy-dispersive X-ray analysis (EDAX). The antimicrobial efficacy of phyto-synthesized CuONPs, both alone and in combination with the antibiotic cefepime, was assessed through disk diffusion, minimum inhibitory concentration (MIC) assays, and in vivo experimentation. The phyto-synthesized CuONPs were characterized as crystalline, hexagonal in shape, and less than 30 nm in size. The antimicrobial efficacy was confirmed by inhibition zones ranging from 12 to 14 mm against multidrug-resistant Klebsiella pneumoniae. The CuONPs showed strong antimicrobial activity, with a minimum inhibitory concentration (MIC) of 2.25 µg/mL against the pathogenic strain. In comparison, cefepime alone showed no antimicrobial activity. Notably, when CuONPs were combined with cefepime, a synergistic effect was observed, lowering the MIC to 1.92 µg/mL. This study addresses the in vitro and in vivo analysis of CuONPs, with cefepime exerting a potent synergistic effect against the multidrug-resistant strain Klebsiella pneumoniae. This combined treatment resulted in an 82% inhibition rate, a significant reduction in bacterial burden, improved histopathological profiles, faster wound healing, and a regulated immune response.
Indexed as
Identifiers
41085779What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.